ACC.13 Opening Session and Late-Breaking Clinical Trials – Session 300
8–10 a.m. PST (UTC - 8 hours)

PREVAIL: Final Results of Randomized Trial of Left Atrial Appendage Closure Versus Warfarin for Stroke/Thromboembolic Prevention in Patients with Non-Valvular Atrial Fibrillation David Holmes, MD, Mayo Clinic, Minn. (Not presented at ACC due to an embargo break)  Summary slide | Video discussion | Discussion MP3 (download) Related Information Abstract - Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients With Atrial Fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) Trial Circulation. 127(6):720-729, February 12, 2013. Reddy, Vivek Y. MD; Doshi, Shephal K. MD; Sievert, Horst MD; Buchbinder, Maurice MD; Neuzil, Petr MD, PhD; Huber, Kenneth MD; Halperin, Jonathan L. MD; Holmes, David MD

---

HPS2-THRIVE: Randomized Comparison Of Extended-Release (ER) niacin/laropiprant 2g Daily Versus Placebo in 25,673 Patients At High Risk Of Occlusive Vascular Events Prof. Jane Armitage, FRCP, Oxford University, Oxford, England Presentation slides  | Summary slide  |  Video interview  | Video discussion    Related Information AHA Science News Video - ESC 2012

 

• Approximately every 34 seconds, an American will experience a coronary event, and approximately every minute, someone will die of one.
• Lifetime risk for developing CVD at age 45 is 2 in 3 for men and 1 in 2 for women.
• This year, about 635,000 Americans will have a new coronary attack, and about 280,000 will have a recurrent attack.
• About 29% of patients with MI are patients with STEMI.
• Average age at first MI is 64.5 years for men and 70.3 years for women.
• The estimated average number of years of life lost because of an MI is 16.6.